Gu Y, Sebaratnam DF. GLP-1 receptor agonists for hidradenitis suppurativa: navigating benefits, risks, and ethical considerations. Int J Dermatol. 2024;63(5):e100–1. https://doi.org/10.1111/ijd.17108.

Article  CAS  PubMed  Google Scholar 

Paschou IA, Sali E, Paschou SA, Psaltopoulou T, Nicolaidou E, Stratigos AJ. The effects of GLP-1RA on inflammatory skin diseases: a comprehensive review. J Eur Acad Dermatol Venereol. 2025;39(12):2047–55. https://doi.org/10.1111/jdv.20694.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mintoff D, Agius R, Benhadou F, Das A, Frew JW, Pace NP. Obesity and hidradenitis suppurativa: targeting meta-inflammation for therapeutic gain. Clin Exp Dermatol. 2023;48(9):984–90. https://doi.org/10.1093/ced/llad182.

Article  PubMed  Google Scholar 

Khalaf R, Davalan W, AlHusayen R. Effectiveness of weight loss drugs in the management of hidradenitis suppurativa: a systematic review. J Cutan Med Surg. 2024;28(6):614–5. https://doi.org/10.1177/12034754241285592.

Article  CAS  PubMed  Google Scholar 

Ingram JR. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):990–8. https://doi.org/10.1111/bjd.19435.

Article  PubMed  Google Scholar 

Henry T, et al. Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa. Int J Dermatol. 2023;62(12):1543–4. https://doi.org/10.1111/ijd.16892.

Article  CAS  PubMed  Google Scholar 

Vilarrasa E, et al. Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases. Actas Dermosifiliogr. 2024;115(1):T56–65. https://doi.org/10.1016/j.ad.2023.10.019.

Article  CAS  PubMed  Google Scholar 

Persson C, Eaton A, Mayrovitz HN. A closer look at the dermatological profile of GLP-1 agonists. Diseases. 2025;13(5):127. https://doi.org/10.3390/diseases13050127.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Javorsky E. Hidradenitis suppurativa: patient experiences with bariatric surgery. J Am Acad Dermatol. 2013;68(4 Suppl):AB89. https://doi.org/10.1016/j.jaad.2012.12.370.

Article  Google Scholar 

Sivanand A, Gulliver WP, Josan CK, Alhusayen R, Fleming PJ. Weight loss and dietary interventions for hidradenitis suppurativa: a systematic review. J Cutan Med Surg. 2020;24(1):64–72. https://doi.org/10.1177/1203475419874412.

Article  PubMed  Google Scholar 

Gallagher C, Kirthi S, Burke T, O’Shea D, Tobin AM. Remission of hidradenitis suppurativa after bariatric surgery. JAAD Case Rep. 2017;3(5):436. https://doi.org/10.1016/j.jdcr.2017.06.008.

Article  PubMed  PubMed Central  Google Scholar 

Lal K, Herringshaw E. The use of GLP-1 agonists in the management of cutaneous disease. J Clin Aesthet Dermatol. 2024;17(9):34. https://pmc.ncbi.nlm.nih.gov/articles/PMC11386968/.

Rivera FB, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024;18(17):100679. https://doi.org/10.1016/j.ajpc.2024.100679.

Article  PubMed  PubMed Central  Google Scholar 

Sattar N, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653–62. https://doi.org/10.1016/S2213-8587(21)00203-5.

Article  CAS  PubMed  Google Scholar 

Parvathaneni A, et al. Exploring the therapeutic potential of GLP-1 agonists in hidradenitis suppurativa. J Drugs Dermatol. 2025;24(4):422–3.

PubMed  Google Scholar 

Krajewski PK, Złotowska A, Szepietowski JC. The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects. J Clin Med. 2024;13(21):6292. https://doi.org/10.3390/jcm13216292.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Emtestam L, Sartorius K. Glucagon-like peptide-1 agonists for treatment of hidradenitis suppurativa. Br J Dermatol. 2017;177(3):625–7. https://doi.org/10.1111/bjd.15742.

Article  CAS  PubMed  Google Scholar 

Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.

Article  PubMed  PubMed Central  Google Scholar 

Encarnacion IN, Desir N, Anusionwu I, Ogunleye T, Taylor S. 62064 The role of GLP-1 agonists in overweight and obese hidradenitis suppurativa patients: a retrospective analysis. J Am Acad Dermatol. 2025;93:AB324. https://doi.org/10.1016/j.jaad.2025.05.1277.

Article  Google Scholar 

Posada MI, Alora MB, Lima XTV. Impact of semaglutide use in obese and diabetic patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2025;39(8):e662–4. https://doi.org/10.1111/jdv.20392.

Article  CAS  Google Scholar 

Rames MM, Alavi A, Aghazadeh N. GLP-1 agonists in patients with hidradenitis suppurativa: a case series. J Cutan Med Surg. 2025. https://doi.org/10.1177/12034754251320045.

Article  PubMed  Google Scholar 

Nicolau J, et al. Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa. Med Clin (Barc). 2024;162(3):118–22. https://doi.org/10.1016/j.medcli.2023.11.007.

Article  PubMed  Google Scholar 

Drumm C, et al. 42762 Successful treatment of hidradenitis suppurativa with semaglutide. J Am Acad Dermatol. 2023;89:AB89. https://doi.org/10.1016/j.jaad.2023.07.359.

Article  Google Scholar 

Jennings L, et al. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br J Dermatol. 2017;177(3):858–9. https://doi.org/10.1111/BJD.15233.

Article  CAS  PubMed  Google Scholar 

Khandalavala BN. A disease-modifying approach for advanced hidradenitis suppurativa (regimen with metformin, liraglutide, dapsone, and finasteride): a case report. Case Rep Dermatol. 2017;9(2):70–8. https://doi.org/10.1159/000473873.

Article  PubMed  PubMed Central  Google Scholar 

Gouvrion L, Delage M, Villani AP, et al. Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa. JAMA Dermatol. 2025;161(10):1084–6. https://doi.org/10.1001/jamadermatol.2025.2723.

Article  PubMed  PubMed Central  Google Scholar 

Romanelli S, et al. 62918 The effect of glucagon-like peptide (GLP)-1 agonists on hidradenitis suppurativa disease severity and musculoskeletal symptoms: a Quality Improvement Initiative by International Dermatology Outcome Measures (IDEOM). J Am Acad Dermatol. 2025;93:AB88. https://doi.org/10.1016/j.jaad.2025.05.356.

Article  Google Scholar 

Chan LJ, Kaur M, Kaffenberger BH. A case of recalcitrant hidradenitis suppurativa concomitantly treated with tirzepatide. JAAD Case Rep. 2024;52:101–2. https://doi.org/10.1016/j.jdcr.2024.02.023.

Article  PubMed  PubMed Central  Google Scholar 

Gupta R, et al. Patient-reported outcomes of glucagon-like peptide-1 agonists on hidradenitis suppurativa severity’. JAAD Int. 2025;21:40–3. https://doi.org/10.1016/j.jdin.2025.05.004.

Article  PubMed  PubMed Central  Google Scholar 

Lyons D, et al. Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life. Br J Dermatol. 2024;191(4):631–3. https://doi.org/10.1093/bjd/ljae216.

Article  PubMed  Google Scholar 

Salem Y, et al. GLP-1 medications are associated with improved outcomes in hidradenitis suppurativa. Gulf Coast Division GME Research Day. 2025 [Conference abstract]. Available from: https://scholarlycommons.hcahealthcare.com/gulfcoast2025/76

Hill M, Bordeaux J. 60888 Semaglutide weight loss effects on hidradenitis suppurativa severity. J Am Acad Dermatol. 2025;93:AB81. https://doi.org/10.1016/j.jaad.2025.05.329.

Article